Verastem | VSTM - Cash And Equivalent


Verastem reported $204.99M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
AbbVie USD 9.39B 4.16B Mar/2026
Alaunos Therapeutics USD 354K 1.03M Mar/2026
AstraZeneca USD 7.56B 1.85B Mar/2026
Curis USD 10.14M 10.14M Jun/2025
Cytokinetics USD 129.84M 7.32M Mar/2026
Gilead Sciences USD 7.56B 234M Dec/2025
Incyte USD 4.02B 435.22M Mar/2026
Laboratory Of America USD 981.1M 448.8M Mar/2026
Novartis USD 6.88B 4.56B Mar/2026
Pfizer USD 1.7B 561M Mar/2026
Roche Holding CHF 7.55B 579M Jun/2025
TG Therapeutics USD 442.21M 242.7M Mar/2026
Verastem USD 204.99M 67.28M Dec/2025